🚨 Bioverge Access Fund 4 is now accepting investors! Leverage Bioverge expertise and back 15 leading healthcare startups through a single investment. Learn more and invest

Ancilia Presentation and Q&A with CEO Alexandra Sakatos

Ancilia is a computational bio-platform company that engineers phage-resistant bacterial therapeutics utilizing CRISPR/Cas to treat microbiome-linked diseases including inflammatory bowel disease (IBD) and immunotherapy-associated colitis.

Bw2gqkertky2gmjeoyfr
Bw2gqkertky2gmjeoyfr